Sickle beta-thalassemia is a rare variant of sickle cell disease (SCD) that manifests with milder symptoms. Musculoskeletal complications arising from this condition can mimic inflammatory arthritis and hence delay the diagnosis of rheumatoid arthritis (RA) until irreversible damage has been done. RA has been reported to occur with SCD but there is no documented literature thus far on its co-occurrence with sickle beta-thalassemia. This case report elucidates the etiopathogenesis, clinical manifestations, and challenges encountered with the diagnosis and management of RA in a patient with sickle beta thalassemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457301 | PMC |
| http://dx.doi.org/10.7759/cureus.17378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.
J Clin Aesthet Dermatol
February 2025
Ms. Romanelli and Dr. Gottlieb are with the Department of Dermatology and Department of Medicine, Division of Rheumatology at Icahn School of Medicine at Mount Sinai in New York, New York.
Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico.
View Article and Find Full Text PDFMajor adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study.
Ther Adv Musculoskelet Dis
March 2025
Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 40705, Taiwan.
Background: Rheumatoid arthritis (RA) is complicated by a high risk of cardiovascular disease and requires the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for persistently active disease despite first-line therapies. The influence of b/tsDMARDs, especially tsDMARDs, on cardiovascular risk in Taiwanese patients with RA remains unclear.
Objectives: To compare the risk of major cardiovascular adverse events (MACEs) or venous thromboembolism (VTE) amongst RA patients initiating approved b/tsDMARDs for up to 5 years.
Emodin mitigates rheumatoid arthritis through direct binding to TNF-α.
Front Pharmacol
February 2025
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, China.
Emodin has shown certain anti-rheumatoid arthritis (RA) activity in preliminary studies. However, the precise mechanisms of emodin's anti-RA effects, particularly its direct targets, remain unclear. This study aimed to evaluate the anti-RA activity of emodin and elucidate its potential mechanisms, with a specific focus on identifying its molecular targets.
View Article and Find Full Text PDF[Rheumatoid arthritis resistant to our treatments, what to do?].
Rev Med Suisse
March 2025
Service de rhumatologie, Hôpital cantonal de Fribourg, 1708 Fribourg.
Rheumatoid arthritis (RA) can be classified as « resistant » or « difficult to treat » when there is no response to multiple lines of treatment and/or persistent symptoms that reduce the patients quality of life. Resistant RA represents a high-risk population for comorbidities. These patients often have more comorbidities, more extra-articular manifestations of their RA, have more disadvantaged social backgrounds, and frequently receive fewer conventional disease-modifying antirheumatic drugs.
View Article and Find Full Text PDF[Treatments de-escalation in rheumatoid arthritis].
Rev Med Suisse
March 2025
Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.
The number of rheumatoid arthritis patients in clinical remission has increased dramatically. We owe this progress to the advent of biotherapy in the 1990s, but also to a more focused therapeutic approach. Managing remission is therefore a contemporary challenge and raises many questions: Do biotherapies lead to a cure or to drug-induced remission? What are the chances of reducing or stopping treatment? What factors are associated with successful discontinuation? How and in what order to proceed when patients are taking several treatments at the same time? In this article, concrete, pragmatic answers based on the latest recommendations and current knowledge are provided.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!